These findings support the value of the use of ANXA1 in various glomerular disorders as (1) a universal diagnostic and prognostic biomarker, (2) a noninvasive urinary early marker that can help in the differential diagnosis of the progressive types of glomerular disorders that can cause nephrotic syndrome from MCD, the most common, but favorable, type of glomerular disorder, and (3) a potential index for differentiating systemic diseases with kidney involvement from primary glomerular disorders. Here, ANXA1 is linked to nephrotic syndrome.